Fulgent Genetics, Inc. (NASDAQ: FLGT) reported Q1 EPS of ($0.36), $0.25 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $71.1 million versus the consensus estimate of $72.68 million.

GUIDANCE:

Fulgent Genetics, Inc. sees FY2026 EPS of ~($1.59), versus the consensus of ($1.36). Fulgent Genetics, Inc. sees FY2026 revenue of ~$350 million, versus the consensus of $349.5 million.

For earnings history and earnings-related data on Fulgent Genetics, Inc. (FLGT) click here.